CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 104 enrolled
Drug / intervention
Semaglutide +1 moredrug
Likely dose
Semaglutide 0.25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04189848
NCT04189848Phase 4Completed
CompareCT.gov

A Trial to Complare the Injection Site Pain Experience of Semaglutide 0.25 mg and Dulaglutide 0.75 mg Administered sc

Novo Nordisk A/S·interventional·Posted Dec 6, 2019·Updated Nov 7, 2022

In Brief

A Phase 4 clinical trial evaluating Semaglutide and Dulaglutide for Healthy Volunteers and 3 related conditions. Completed, enrolled 104 participants across 1 site.

Detailed Summary

This study in healthy men and women looks at the injection site experience of semaglutide and dulaglutide given subcutaneously (s.c., under the skin). Participants will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day. The 2 injections will be given at least 30 minutes apart, one in each side of the stomach. Participants will be in the clinic research center for 1 day. A follow-up phone call will take place between 4 and 5 weeks after the injections were given.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers, Diabetes Mellitus, Type 2, Overweight, Obesity
CountriesNetherlands
Collaborators--

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedDec 6, 2019
Enrollment StartDec 3, 2019
Primary CompletionJan 29, 2020
Study CompletionFeb 27, 2020
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 6.6 years ago

Interventions

Semaglutidedrug

Subjects will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day.

Dulaglutidedrug

Subjects will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day.